bioMérieux and Biocartis have mutually agreed to end their collaboration to develop and commercialise an integrated molecular biology system. Renouncing to its rights relating to Biocartis' technology in particular in molecular microbiology, bioMérieux will depreciate their corresponding net accounting value and will book a corresponding non-cash expense amounting to EUR6mn in non-recurring items in 2013. bioMérieux will, however, remain a Biocartis shareholder.
Both companies will be free to pursue their development in molecular biology independently. In particular, this decision will let bioMérieux focus its R&D and sales and marketing resources and investments on other molecular biology programmes. bioMérieux will target nucleic acid extraction, where the company's easyMAG system has a leading position, and the diagnosis of infectious diseases, its core strategic area. In this particular field, it will leverage the Argene range of assays dedicated to immuno-compromised patients , commercialise the Ras tests primarily in India and, over the medium term, in emerging markets and finalise the acquisition of BioFire.
BioFire, a US-based company, specialised in molecular biology invented, manufactures and commercialises FilmArray, an integrated multiplex PCR system dedicated to infectious disease diagnosis in specialised or decentralised hospital laboratories. FilmArray respiratory and blood culture panels have been CE-marked and cleared by the FDA.